Invention Grant
US09320807B2 Drug delivery of temozolomide for systemic based treatment of cancer
有权
用于系统性治疗癌症的替莫唑胺的药物递送
- Patent Title: Drug delivery of temozolomide for systemic based treatment of cancer
- Patent Title (中): 用于系统性治疗癌症的替莫唑胺的药物递送
-
Application No.: US14179195Application Date: 2014-02-12
-
Publication No.: US09320807B2Publication Date: 2016-04-26
- Inventor: Rameshwar Patil , Eggehard Holler , Keith L. Black , Julia Y. Ljubimova
- Applicant: CEDARS-SINAI MEDICAL CENTER
- Applicant Address: US CA Los Angeles
- Assignee: CEDARS-SINAI MEDICAL CENTER
- Current Assignee: CEDARS-SINAI MEDICAL CENTER
- Current Assignee Address: US CA Los Angeles
- Agency: Volpe and Koenig, P.C.
- Main IPC: A61K38/00
- IPC: A61K38/00 ; A61K31/74 ; A61K47/48 ; C08G63/48 ; C08G63/91 ; C08L89/00 ; C08F283/00 ; C08G69/48 ; C08L67/00 ; C08L77/00 ; A61K31/425
Abstract:
The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.
Public/Granted literature
- US20140161762A1 DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER Public/Granted day:2014-06-12
Information query
IPC分类:
